GlassScriptPhysician profile
Richard David Carpenter
NPI 1881127165
$4,518.85
in general payments reported to CMS, 2019-2025
30 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.88 · 2021: $586 · 2022: $738 · 2023: $891 · 2024: $1,061 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,146 · Education: $4.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.02 |
| Education | $4.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $978.32 | 2022-2025 | Caplyta |
| Abbvie INC. | $787.08 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $458.32 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lundbeck LLC | $453.66 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $285.08 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $241.00 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $169.12 | 2021 | |
| Lilly USA, LLC | $152.13 | 2021-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $115.07 | 2022-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $99.98 | 2022 | |
| Pfizer INC. | $90.52 | 2023-2025 | |
| Novo Nordisk INC | $89.03 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $68.82 | 2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.17 | 2022-2025 | Jardiance |
| Indivior INC. | $65.88 | 2024-2025 | Sublocade |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $48.57 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $46.37 | 2024 | Repatha, Otezla |
| Alkermes, INC. | $40.03 | 2022 | |
| Axsome Therapeutics, INC. | $38.26 | 2023 | Auvelity |
| Ipsen Biopharmaceuticals, INC | $32.93 | 2025 | Dysport |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.49 | 2025 | Xifaxan |
| Vertex Pharmaceuticals Incorporated | $30.40 | 2025 | |
| Bausch Health US, LLC | $22.77 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.71 | 2025 | Zoryve |
| Allergan, INC. | $19.33 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.35 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $15.24 | 2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $13.33 | 2021 | |
| Horizon Therapeutics Plc | $12.80 | 2022 | |
| Mayne Pharma Commercial LLC | $6.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.